Macquarie tips 28% upside for this ASX healthcare stock

The broker expects big things from this New Zealand retirement village developer and operator.

| More on:
An older gentleman leans over his partner's shoulder as she looks at a tablet device while seated at a table.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investor interest in ASX healthcare stocks has climbed recently. The S&P/ASX 200 Healthcare Index (ASX: XHJ) dropped overall in FY25 but appears to have made some recovery so far in July.

As of lunchtime today, the index is 0.89% higher and has climbed 1.28% over the past five days. For the year to date, the index is 9.26% higher.

And continued momentum and strong potential upside for one ASX healthcare stock could drive the sector higher.

Summerset Group Holdings Ltd (ASX: SNZ) shares are flat at $11.00 as of midday today but have jumped 30.49% over the year. Over the past three months, the New Zealand retirement village developer and operator's share price has climbed 11.22%.

Here's what Macquarie Group Ltd (ASX: MQG) thinks of the stock.

Macquarie revises Summerset Group's target price

Macquarie maintains its outperform rating on Summerset Group and has raised its target price to NZ$15.75, up from NZ$15.35. As of midday today, the company's shares are trading at NZ$12.02.

The revised target price represents a potential 28% upside for the stock.

The company is dual-listed on the ASX and the NZX, which means local Australian investors could also benefit from any potential upside.

In a note to investors, the broker said the company's new sales reached a record volume in Q2 2025, up 42% compared with the previous corresponding period, and 68% higher than Q1.

Total sales for the first half of 2025 are 22% higher period-on-period, making it a record half-yearly result for the business. 

Summerset Group has seen "road-based improvement in sales and noted uncontracted new stock decreased 6% in the period and contracted stock increased by 50%."

"Australia saw 9 sales over the period, in line with FY24 contracts."

The company's resales volumes also meant it achieved the best Q2 on record and the second-best quarter overall. 

"A combination of offering, improved housing market, competitor disruptions and sales team effectiveness is underpinning strong sales and contracting will drive 2H25 growth. Upside risk to FY25 earnings is emerging, while SUM's overall growth outlook remains attractive," the broker said in its investor note. 

"Key risks include quantum and speed of improvement in housing market conditions, and associated impact on sales including St Johns. Success and speed of ramp-up in Australia is a key driver of growth in the medium to long term."

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group. The Motley Fool Australia has positions in and has recommended Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Excited couple celebrating success while looking at smartphone.
Healthcare Shares

Up 680% since July, here's why 2025 was a breakout year for this hot ASX stock

With consistent contract wins, FDA clearance, and backing from Pro Medicus, 4D Medical is showing that there is a commercial…

Read more »

Shot of a senior scientist looking stressed out while working in a lab.
Healthcare Shares

After soaring 40% in 2 weeks, this ASX All Ords healthcare stock has been downgraded

Here’s what analysts at Macquarie rate the stock as now.

Read more »

A little boy, soon to be a brother, kisses and holds his mum's pregnant tummy.
Healthcare Shares

Own NIB shares? Here are the key dates for 2026

NIB has released its corporate calendar, including dividend dates, for 2026.

Read more »

A male doctor wearing a white lab coat shrugs his shoulders and holds his hands up in the air looking confused
Healthcare Shares

ASX healthcare stock debuts at a massive discount to its initial public offer price

Saluda Medical shares have had a difficult start to public life, trading well below the initial public offer price.

Read more »

Red buy button on an apple keyboard with a finger on it representing asx tech shares to buy today
Healthcare Shares

Why CSL shares now look 'massively oversold'

A leading investment expert says ASX investors have a rare chance to buy CSL shares at a discount.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Which junior biotech's shares are flying on positive trial news?

This company's shares have surged higher after positive clinical trial results for its stroke treatment drug.

Read more »

Excited elderly woman on a swing.
Healthcare Shares

Guess which ASX 300 healthcare share is lifting off on $25 million news

The ASX 300 healthcare share is grabbing investor interest on Thursday. Let’s see why.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Doomed takeover bid for Mayne Pharma to come to an end

The Mayne Pharma takeover saga appears to be finally drawing to an end, with shareholders bearing the pain of the…

Read more »